Genomic Score Helped Predict Cancer Treatment Survival
A new scoring system may help doctors identify patients with neuroendocrine neoplasms who are most likely to benefit from immunotherapy.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Should medical breakthroughs be prioritized primarily by survival outcomes over other factors?
Researchers have developed a genomic score that predicts survival outcomes for patients with neuroendocrine neoplasms treated with immune checkpoint inhibitors. The findings may help clinicians better personalize care decisions for this complex diagnosis.
Why it matters
Currently, no validated tools exist to help physicians identify which patients with neuroendocrine neoplasms will likely respond to immunotherapy. This score offers a potential method to estimate survival benefits before beginning treatment.
In a study of 54 patients, researchers analyzed a genomic score derived from 70 genes across 24 functional domains. Patients with a score of 2 or higher experienced significantly longer survival compared to those with lower scores, a finding later validated in a 1,661-patient pan-cancer cohort.
The players
OSUCCC-James
The Ohio State University Comprehensive Cancer Center is a major research institution focused on developing innovative cancer diagnostics and therapies.
The Oncologist
A peer-reviewed medical journal that publishes original research and clinical studies on cancer care and therapeutic advances.
The details
The genomic score functions by calculating the difference between positive and negative gene alteration scores identified within tumor samples. These genes influence how the body interacts with immune checkpoint inhibitors, such as nivolumab or ipilimumab. By quantifying these genetic markers, the score helps indicate whether a patient's neuroendocrine neoplasm is likely to respond to the therapy.
Timeline
Patients were treated at OSUCCC-James between 2017 and 2023.
The study findings were published in The Oncologist in September 2026.
Health Landscape
The use of immune checkpoint inhibitors in neuroendocrine neoplasms remains a complex area of oncology with limited predictive markers. This research represents an advancement in precision medicine by applying genomic profiling to estimate survival outcomes in this specialized patient population.
If you or a loved one are considering immunotherapy for neuroendocrine neoplasms, it is worth discussing with your oncology team whether genomic testing might inform your care plan. Understanding if a center utilizes predictive scoring systems can help you and your doctor evaluate potential treatment responses.
The takeaway
This genomic score offers a new way to help predict which patients might benefit most from checkpoint inhibitor therapy. Patients should talk to their oncology team about whether available biomarker testing can provide clarity on their treatment outlook.
Further reading
Learn more about the latest research and diagnostic tools in Cancer.
More information
Review the original results in the scientific study reference.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should medical breakthroughs be prioritized primarily by survival outcomes over other factors?
